We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
+69.51%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$176M
AUM Growth
+$61.6M
Cap. Flow
+$7.76M
Cap. Flow %
4.4%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$7.76M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.39B
$116M 65.62%
4,639,304
+350,000
+8% +$7.76M
ALMS
2
Alumis Inc
ALMS
$3.57B
$18.4M 10.45%
4,619,803
– –
ALXO icon
3
ALX Oncology
ALXO
$273M
$17.8M 10.06%
9,699,925
– –
HRMY icon
4
Harmony Biosciences
HRMY
$2.04B
$13.5M 7.64%
489,194
– –
LYEL icon
5
Lyell Immunopharma
LYEL
$309M
$7.69M 4.36%
473,479
– –
ARTV
6
Artiva Biotherapeutics
ARTV
$487M
$3.3M 1.87%
1,148,975
– –

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q3 2025 Portfolio in Review

As of Q3 2025, venBio Partners held 6 positions worth $176M, up 54% from $115M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $7.76M of net new capital in Q3 2025, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners added most to Pharvaris in Q3 2025, an estimated $7.76M increase.
  • venBio Partners's ten largest holdings make up 100% of its $176M portfolio in Q3 2025.
  • venBio Partners opened 0 new positions and closed 0 in Q3 2025.
  • venBio Partners's portfolio value rose 54% quarter-over-quarter to $176M.

Based on venBio Partners's 13F filing for Q3 2025, filed 14 Nov 2025.